Probiogen AG
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Jun 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 20, 2027The maintenance fee for Enhancement of protein production yield mediated by a fast shuttling CDC42 GTPase (US 9,163,089) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Depletion of host cell components from live vector vaccines (US 9,273,289) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,815,540 | Productivity augmenting protein factor, novel cell lines and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,642,292 | Process for producing molecules containing specialized glycan structures In force · From the USPTO record | In force | From the USPTO record | |
| US 8,940,534 | Immortalized avian cell lines for virus production In force · From the USPTO record | In force | From the USPTO record | |
| US 8,911,995 | Culture system and method for immunogenicity and immunofunction testing in vitro In force · From the USPTO record | In force | From the USPTO record | |
| US 9,273,289 | Depletion of host cell components from live vector vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,163,089 | Enhancement of protein production yield mediated by a fast shuttling CDC42 GTPase In force · From the USPTO record | In force | From the USPTO record | |
| US 9,732,325 | MVA virus and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,060,069 | Porcine cell line for virus production In force · From the USPTO record | In force | From the USPTO record | |
| US 11,104,884 | Vaccinia virus vectors related to MVA with extensive genomic symmetries In force · From the USPTO record | In force | From the USPTO record | |
| US 11,999,975 | Method For Purifying An Enveloped Virus In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 6 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 1 abandoned · 4 no status recorded